Intravitreal faricimab as an adjuvant in the management of tubercular uveitis.

Yasmine AlcibahyKarina JulianM Fernanda BonillaAli MohamedSarah AmraniAniruddha Kishandutt Agarwal

Published in: Retinal cases & brief reports (2023)

Intravitreal faricimab, given its angiopoietin-2 (ang2) inhibition and anti-vascular endothelial growth factor action, maybe a helpful adjunct in IOTB. Whether ang2 inhibition provides any additional benefit needs further evaluation in extensive studies.

Keyphrases

vascular endothelial growth factor
angiotensin ii
endothelial cells
early stage
juvenile idiopathic arthritis
ankylosing spondylitis
case control
diabetic retinopathy
systemic lupus erythematosus
clinical evaluation